Yabao and Sciecure Pharma partner to bring generics to US and China markets

Chinese drugmaker Yabao Pharmaceutical (SSE: 600351) and USA-based Sciecure Pharma yesterday announced a strategic partnership to co-develop, manufacture and commercialize high technological barrier generics medicines for both the US and China markets.

Under the terms of the agreement, Yabao will exclusively own rights to commercialize certain Sciecure-developed products in China and to manufacture for both the US and China markets, while Sciecure Pharma will retain rights to commercialize in USA and all other markets. Financial terms were not disclosed.

“Yabao is pleased to collaborate with Sciecure Pharma, a dynamic company with extensive drug development expertise and know-how on high technological barrier controlled release formulation, to synergize with Yabao’s cGMP manufacturing and leading commercialization capabilities in China,” commented Peng Wang, president of R&D at Yabao, adding: “Yabao is actively partnering with leading overseas companies to bring in and deliver high quality medicines with unmet needs in China. This partnership also demonstrates that Yabao’s competitive R&D and manufacturing have expanded into developed markets.”